Tissue Regenix Group PLC Director/PDMR Shareholding (6628M)
15 Settembre 2023 - 5:30PM
UK Regulatory
TIDMTRX
RNS Number : 6628M
Tissue Regenix Group PLC
15 September 2023
Tissue Regenix Group plc
("Tissue Regenix", the "Company" or "the Group")
Director/PDMR Shareholding
Tissue Regenix Group plc (AIM: TRX), the regenerative medical
devices company, announces that on 15 September 2023, Brian
Phillips, Non-Executive Director, bought 6,773 Ordinary Shares in
the Group at a price of 54 pence per share for a total
consideration of GBP3,657.42.
As a result, Brian Phillips holds 160,000 Ordinary Shares in the
Company representing 0.23% of the total issued share capital.
Change of Name of Nominated Adviser and Broker
The Company also announces that its Nominated Adviser and Sole
Broker has changed its name to Cavendish Capital Markets Limited
following completion of its own corporate merger.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer via Walbrook PR
Cavendish Capital Markets Limited (Nominated
Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Alice Woodings/Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical device company in
regenerative medicine. The Company's patented decellularisation
technology (dCELL(R)) removes DNA and other cellular material from
animal and human soft tissue, leaving an acellular tissue scaffold
not rejected by the patient's body that can be used to repair
diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R). This biotech company specialises in regenerative
medicine and is dedicated to developing high-quality, innovative
tissue scaffolds to enhance healing opportunities in defects
created by trauma and disease. CellRight's human tissue products
may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Brian Phillips
--------------------------------------- ---------------------------------------
Reason for the notification
2
--------------------------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------------------------- ---------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------------------------- ---------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1p each
financial instrument,
type of instrument
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
0.54 6,773
----------------- -----------------
d) Aggregated information
- Aggregated volume 6,773
- Price GBP3,657.42
e) Date of the transaction 15 September 2023
--------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBUGDCLDBDGXU
(END) Dow Jones Newswires
September 15, 2023 11:30 ET (15:30 GMT)
Grafico Azioni Tissue Regenix (LSE:TRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Tissue Regenix (LSE:TRX)
Storico
Da Mag 2023 a Mag 2024
